News Center

News Center

The latest clinical updates and product development news from Progenity.

Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced the pricing of its initial public offering.

The four posters were released for the 2020 American College of Medical Genetics and Genomics’ (ACMG) Annual Clinical Genetics Meeting.

Mr. Silvestry will be focused on delivering operational excellence, achieving ambitious growth targets, and driving the company’s service culture.

Mr. Seelye will help to strengthen our technology and data strategy, leading the development of key products and services designed to transform the customer experience.

Our lab is fully operational and we are offering assisted patient education and collection services to support healthcare providers and patients.

We will present results from clinical laboratory experience that indicate noninvasive prenatal testing (NIPT) performs well for predicting aneuploidies in twin pregnancies.

Highlighting our work to improve the diagnosis and management of patients with small intestinal bacterial overgrowth (SIBO).

Highlighting Opportunities for Technologies Aimed at Improving Diagnosis and Treatment of Gastrointestinal Disorders